Cerenome, Inc.
CNSY Healthcare Biotechnology
Cerenome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5.2 million, down 10.5% from fiscal 2024. In the quarter to June 2026, revenue fell 70.4%, EPS fell 362.0% and free cash flow fell 31.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CNSY
Cerenome, Inc. (CNSY) Altman Z-score
Cerenome, Inc.'s Altman Z-score for fiscal 2025 is −44.87, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −44.87 | 67.29 |
| FY2024 | −112.16 | (49.82) |
| FY2023 | −62.34 | (33.00) |
| FY2022 | −29.33 | 22.74 |
| FY2020 | −52.07 | (26.59) |
| FY2019 | −25.48 | 0.09 |
| FY2018 | −25.57 | (5.93) |
| FY2017 | −19.64 | (124,343.82) |
| FY2016 | 124324.19 | 6,286.07 |
| FY2015 | 118038.12 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.17 | — | 0.21 | |
| Retained earnings / total assets | (31.60) | — | −44.24 | |
| EBIT / total assets | (0.94) | — | −3.09 | |
| Market value of equity / total liabilities | 3.22 | — | 1.93 | |
| Sales / total assets | 0.32 | — | 0.32 | |
| Altman Z-score | Distress zone | −44.87 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −107.82 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| KTTA Pasithea Therapeutics Corp. compare | 3.0× |
| TVRD Tvardi Therapeutics, Inc. compare | −5.1× |
| LPCN Lipocine Inc. compare | −7.7× |
| DARE Dare Bioscience, Inc. compare | −8.9× |
| ADAPY Adaptimmune Therapeutics PLC compare | −23.3× |
| CNSY Cerenome, Inc. | −44.9× |
| BCDA BioCardia, Inc. compare | −74.8× |
| RVLP RVL Pharmaceuticals PLC compare | — |
| CLVSQ Clovis Oncology, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets